Tourmaline Bio, Inc. ( (TRML) ) has released its Q1 earnings. Here is a breakdown of the information Tourmaline Bio, Inc. presented to its investors.
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, with a lead asset in pacibekitug. In its first quarter of 2025 financial report, Tourmaline Bio highlighted its ongoing clinical trials and financial status. The company is on track with its Phase 2 TRANQUILITY trial for pacibekitug, targeting cardiovascular inflammation, and anticipates reporting topline data in the second quarter of 2025. Additionally, Tourmaline is progressing with its spiriTED trial for thyroid eye disease, with results expected in the second half of 2025. Financially, Tourmaline reported a cash position of $275.3 million, providing a runway into the second half of 2027. The company experienced increased research and development expenses, primarily due to its active clinical trials, resulting in a net loss of $23.0 million for the quarter. Looking ahead, Tourmaline Bio remains focused on advancing pacibekitug through its clinical development stages, with potential expansions into additional indications, positioning the company for future growth in the biotechnology sector.